Comparative Pharmacology
Head-to-head clinical analysis: HALDOL SOLUTAB versus TREMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL SOLUTAB versus TREMIN.
HALDOL SOLUTAB vs TREMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
Trihexyphenidyl is a centrally acting anticholinergic agent that blocks muscarinic acetylcholine receptors in the basal ganglia, restoring the balance between dopaminergic and cholinergic activity, thereby reducing extrapyramidal symptoms.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
1 mg orally 1-2 times daily, gradually increasing by 1 mg every 5-7 days up to 12 mg/day in divided doses. Maximum dose 12 mg/day.
None Documented
None Documented
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
Terminal elimination half-life: 16 hours (range 12–20 hours) in adults, supporting twice-daily dosing; 35 hours in elderly patients
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Renal: 40% unchanged; fecal: 60% as metabolites
Category C
Category C
Antipsychotic
Antipsychotic